FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer

Cancer Genetics and Cytogenetics

Volumn 180, Issue 1, 2008, Pages 1-5

  Kang, Sokbom ^a   Dong, Seung Myung ^a   Seo, Sang Soo ^a   Kim, Jae Weon ^b   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 36749010704     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.09.002     Document Type: Article

References (28)

1. Bosch F.X., and de Sanjose S. Human papillomavirus in cervical cancer. Curr Oncol Rep 4 (2002) 175-183
2. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 342-348
3. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
4. Muschen M., Warskulat U., and Beckmann M.W. Defining CD95 as a tumor suppressor gene. J Mol Med 78 (2000) 312-325
5. O'Connell J., O'Sullivan G.C., Collins J.K., and Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184 (1996) 1075-1082
6. Suda T., Takahashi T., Golstein P., and Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75 (1993) 1169-1178
7. Lee S.H., Shin M.S., Park W.S., Kim S.Y., Dong S.M., Pi J.H., Lee H.K., Kim H.S., Jang J.J., Kim C.S., Kim S.H., Lee J.Y., and Yoo N.J. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59 (1999) 3068-3072
8. Gastman B.R., Atarshi Y., Reichert T.E., Saito T., Balkir L., Rabinowich H., and Whiteside T.L. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59 (1999) 5356-5364
9. Viard-Leveugle I., Veyrenc S., French L.E., Brambilla C., and Brambilla E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 201 (2003) 268-277
10. Lee S.H., Shin M.S., Park W.S., Kim S.Y., Kim H.S., Han J.Y., Park G.S., Dong S.M., Pi J.H., Kim C.S., Kim S.H., Lee J.Y., and Yoo N.J. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18 (1999) 3754-3760
11. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., Green D.R., and Kratzke R.A. Human lung carcinomas express Fas ligand. Cancer Res 57 (1997) 1007-1012
12. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., Roche D., Collins J.K., and Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160 (1998) 5669-5675
13. Huang Q.R., Morris D., and Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34 (1997) 577-582
14. Sibley K., Rollinson S., Allan J.M., Smith A.G., Law G.R., Roddam P.L., Skibola C.F., Smith M.T., and Morgan G.J. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63 (2003) 4327-4330
15. Wu J., Metz C., Xu X., Abe R., Gibson A.W., Edberg J.C., Cooke J., Xie F., Cooper G.S., and Kimberly R.P. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170 (2003) 132-138
16. Contreras D.N., Krammer P.H., Potkul R.K., Bu P., Rossi J.L., Kaufmann A.M., Gissmann L., and Qiao L. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother 23 (2000) 67-74
17. Sun T., Zhou Y., Li H., Han X., Shi Y., Wang L., Miao X., Tan W., Zhao D., Zhang X., Guo Y., and Lin D. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 202 (2005) 967-974
18. Lai H.C., Sytwu H.K., Sun C.A., Yu M.H., Yu C.P., Liu H.S., Chang C.C., and Chu T.Y. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 103 (2003) 221-225
19. Dybikowska A., Sliwinski W., Emerich J., and Podhajska A.J. Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med 14 (2004) 475-478
20. Engelmark M.T., Renkema K.Y., and Gyllensten U.B. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer 112 (2004) 1084-1085
21. Lai H.C., Lin W.Y., Lin Y.W., Chang C.C., Yu M.H., Chen C.C., and Chu T.Y. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol 99 (2005) 113-118
22. Ueda M., Hung Y.C., Terai Y., Yamaguchi H., Saito J., Nunobiki O., Noda S., and Ueki M. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 98 (2005) 129-133
23. Zoodsma M., Nolte I.M., Schipper M., Oosterom E., van der Steege G., de Vries E.G., Te Meerman G.J., and van der Zee A.G. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer (2005) 15(Suppl)3:282-90
24. Ioachim H.L., Decuseara R., Giancotti F., and Dorsett B.H. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases. Pathol Res Pract 200 (2005) 743-751
25. Kase H., Aoki Y., and Tanaka K. Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression. Gynecol Oncol 90 (2003) 70-74
26. Koomagi R., and Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84 (1999) 239-243
27. Nagashima H., Mori M., Sadanaga N., Mashino K., Yoshikawa Y., and Sugimachi K. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol 18 (2001) 1157-1162
28. Younes M., Schwartz M.R., Ertan A., Finnie D., and Younes A. Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 88 (2000) 524-528